GRAIL is facing a securities class action lawsuit following a $2.2 billion wipeout in market capitalization in February 2026. The lawsuit alleges that the company misled investors regarding the design and success probability of its NHS-Galleri cancer screening trial. The significant loss occurred after the clinical trial failed to meet its primary endpoint, leading to ongoing investigations by legal firms into the company's disclosures.
Hagens Berman investigates potential investor deception regarding NHS-Galleri cancer screening trials following a clinical failure and massive valuation loss.
Read the full storyThe biotech firm is accused of misleading investors regarding the design and success probability of its flagship NHS-Galleri clinical trial.
Investors sue biotech firm GRAIL alleging misleading statements regarding cancer-detection trials after a massive $2.2 billion valuation drop.